Lilly QC/QA department
Executive Summary
Lilly VP-Commercialization Networks Frank Deane, PhD, named VP-quality, succeeding Alan Dinner, PhD, who is retiring from the company. Deane and VP-Manufacturing Scott Canute will manage Lilly's responses to FDA on recent manufacturing issues raised by the agency ("The Pink Sheet" March 12, p. 26). Canute and Deane both report to Senior VP-Human Resources & Manufacturing Pedro Granadillo...
You may also be interested in...
Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15
Lilly hopes to be ready for a re-inspection of its intramuscular Zyprexa production facility in mid-May, ahead of the late June user fee deadline for a decision on the new formulation of the antipsychotic.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.